B. Braun Medical Group Pays Out $7.8 Million In Legal Settlement

During National Safety Month, the staggering realities about prescription drug abuse in America often take center stage. With the nonmedical use of prescription drugs growing throughout the country, organizations are taking action to bring awareness about the risks of substance abuse and addiction.

Manufactured to treat non-small cell lung cancer, Tarceva manufacturers exaggerated information about the drug’s uses. Some of the inflated lacked research and evidence. After a whistleblower lawsuit was filed, the case was further investigated. The total legal settlement of $67 million will rectify the manufacturer’s false claim allegations and kickbacks to physicians.

The antibiotic class fluoroquinolones were developed for serious infections; however, they’re frequently prescribed for less severe conditions as well. Now, after more than 30 years on the market, recent research suggests they can lead to dangerous health complications. As a result, drug labels are receiving updates to reflect the new safety information.

Recent studies about the newer class of type 2 diabetes drug, Invokana, show an increased risk of leg, foot and toe amputations. The FDA has since warned individuals and doctors to carefully watch for any warning signs that may occur while taking the drug.

Essure, a permanent birth control device implanted in approximately 750,000 women worldwide, is facing accusations about its connection to serious health complications. Lawsuits filed against the manufacturer state a failure to warn about the risks linked to the device, sometimes leading to life-threatening conditions.

After numerous defective saline syringes sickened hundreds of patients, allegations began piling up against B. Braun Medical Group for distributing the devices. To resolve criminal charges brought against it, the company will pay $7.8 million – $3 million to victims and $4.8 million in penalties and forfeited profit.